Israel Active

Israel’s PsyRx has developed a radically new treatment for depression. It combines an approved medicine from the SSRI family with a low dosage of ibogaine. PsyRx has just completed a successful lab toxicological safety study for the treatment to help it progress to human trials.

Israel’s Madrigal Mental Care is based in Kibbutz Reim – one of the communities devasted by Hamas on Oct 7.  So, it is remarkable that it has just announced the successful completion of its pivotal nanotechnology research on using Ketamine as a treatment for PTSD & depression.

A new Trauma Institute has been established at the Hebrew University of Jerusalem. It will design new clinical approaches to and train therapists to deal with the nationwide traumas following the Oct 7 Hamas attacks. The new Institute has raised 25% of its budget and is seeking support.   (US donors)

Zuckerman Faculty Scholar Dr. Arielle Fischer runs the Fischer Biomechanics and Wearable Technology Lab at Israel’s Technion Institute. Her lab develops biomechanical tools and wearable devices to detect, prevent, and correct musculoskeletal movement disorders.

Rafa Laboratories is one of Israel’s oldest pharmaceutical companies. For example, it has been supplying autoinjectors for over 30 years, for global medical conditions including seizures and now (partnering USA’s BARDA) to counter nerve agent and pesticide poisoning.

Israeli-founded Somite.ai can revolutionize stem cell therapy. Its first target is Duchenne Muscular Dystrophy. When muscle stem cells are injected into an existing muscle, the muscles can rebuild and regain function. Somite will then move on to creating brown fat cells for the treatment of diabetes.

Researchers at Israel’s Weizmann Institute have discovered a benign species of yeast named “Kazachstania weizmannii” in homage to Chaim Weizmann. It prevents the spread of Candida albicans, a strain of yeast which causes candidiasis, a fungal infection responsible for around 200,000 deaths per year.

Israel’s Bonus Biogroup (see previously) has developed microscopic biodegradable tubes that run through an engineered transplant organ, supplying a steady flow of blood. This vastly increases the viability of artificial organs and the success rate of transplant operations.

In 2023, Bar-Ilan University Prof Shai Rahimipour (see previously) worked with Canadian scientists on a peptide therapy for Alzheimer’s disease. Now he is working with Italian scientists developing nanoparticles to attack an early version of the Amyloid-beta protein.

Prof. Ofra Benny, cofounder and CSO of Israel’s Orsight, has developed a small molecule that (in lab tests) stops the formation of excess blood vessels in the eye, thus preventing the worst effects of wet AMD. It also has prospects for use in cutting off blood supply to tumors.